# Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

> **NCT05398094** · PHASE2 · RECRUITING · sponsor: **Fundación GECP** · enrollment: 19 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III
- KRAS P.G12C

## Interventions

- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT05398094
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-21
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398094, "Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05398094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*